稳健医疗(300888) - 2021 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2021 was CNY 2,268,544,975.62, representing a 52.97% increase compared to CNY 1,482,975,289.36 in the same period last year[3]. - Net profit attributable to shareholders was CNY 480,582,571.42, up 50.74% from CNY 318,806,306.55 year-on-year[3]. - The net profit after deducting non-recurring gains and losses was CNY 455,065,047.62, reflecting a 43.12% increase from CNY 317,949,508.13 in the previous year[3]. - Basic earnings per share increased by 33.07% to CNY 1.1268, compared to CNY 0.8468 in the previous year[3]. - Total operating revenue for Q1 2021 reached ¥1,403,053,485.12, a significant increase from ¥881,513,012.68 in the same period last year, representing a growth of approximately 59.1%[42]. - Net profit for Q1 2021 was ¥480,806,327.63, compared to ¥320,042,470.88 in Q1 2020, reflecting a year-over-year increase of about 50.2%[40]. - The company reported a total comprehensive income of ¥481,013,637.78 for Q1 2021, up from ¥320,333,858.36 in Q1 2020, which is an increase of approximately 50.2%[41]. Cash Flow and Liquidity - The net cash flow from operating activities decreased by 69.28% to CNY 187,866,670.61, down from CNY 611,546,751.39 in the same period last year[3]. - Cash received from investment increased by 389.32% to CNY 2.52 billion, attributed to the redemption of financial products[14]. - Cash inflow from operating activities totaled CNY 2,273,919,182.07, up from CNY 2,195,276,740.12 year-over-year[46]. - Cash received from sales of goods and services was CNY 2,204,595,850.27, compared to CNY 2,159,021,644.60 in the same period last year, indicating a growth of approximately 2%[45]. - The company reported a cash and cash equivalents balance of CNY 4,500,657,547.02 at the end of the quarter, up from CNY 879,822,844.73 at the end of the previous year[47]. - The company's cash and cash equivalents increased to RMB 4,513.22 million from RMB 4,162.54 million as of December 31, 2020, reflecting a growth of approximately 8.4%[31]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 13,550,059,545.19, a 4.21% increase from CNY 13,002,251,764.44 at the end of the previous year[3]. - The total liabilities increased to CNY 1,519,906,147.29 from CNY 2,037,718,375.39 year-over-year, indicating a reduction in overall debt levels[37]. - The total assets of the company reached RMB 13,550.06 million, compared to RMB 13,002.25 million at the end of 2020, marking an increase of about 4.2%[32]. - The total liabilities increased from CNY 2,533,861,673.00 to CNY 3,098,196,048.76, reflecting an increase of CNY 564,334,375.76[53]. - The company's total equity attributable to shareholders decreased by CNY 60,128,638.03, from CNY 10,453,934,045.43 to CNY 10,393,805,407.40[53]. Sales and Revenue Breakdown - Medical consumables sales amounted to CNY 1.38 billion, up 67.16% year-on-year, with overseas sales increasing by 404.87% to CNY 596 million[15]. - Health lifestyle consumer products generated sales of CNY 818 million, a 40.38% increase year-on-year, with full cotton products sales reaching CNY 807 million, up 41.39%[15]. - Medical supplies sales reached CNY 1,376,019,757.79 in Q1 2021, a significant increase of 67.15% compared to the same period last year[16]. - The top five customers contributed CNY 461,075,659.08, accounting for 20.32% of total revenue in Q1 2021[20]. - The company confirmed sales revenue of USD 11.7 million from a major contract, with a collection rate of 100%[17]. Investments and Expenditures - Research and development expenses rose by 125.87% to CNY 99.19 million, reflecting increased investment in R&D[13]. - The company has invested 14,923.09 million CNY in the current quarter, with a cumulative investment of 105,104.94 million CNY[24]. - The high-end dressing production line project has a total investment commitment of 21,685.86 million CNY, with 12.25% of the project completed[24]. - The marketing network construction project has a total investment commitment of 70,456.87 million CNY, with 19.80% of the project completed[24]. - The company’s investment in fixed assets and intangible assets amounted to CNY 336,705,004.90, compared to CNY 207,344,502.42 in the previous year[46]. Operational Efficiency - The weighted average return on equity was 4.51%, down 5.09% from 9.60% in the previous year[3]. - The company reported a decrease in employee compensation payable to CNY 127,608,466.45 from CNY 169,957,077.81, indicating improved operational efficiency[33]. - The company executed its annual business plan without significant adjustments during the reporting period[21]. - There were no significant changes in the company’s core technology team or major risks affecting operations during the reporting period[18]. Compliance and Governance - The company has not reported any non-compliance with external guarantees during the reporting period[27]. - There were no non-operational fund occupations by controlling shareholders or related parties during the reporting period[27]. - The first quarter report was not audited, indicating preliminary financial data[56].